Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.63 |
| ▸ | MAPT | P10636 | 6/20 | 0.63 |
| ▸ | TP53 | P04637 | 8/20 | 0.58 |
| ▸ | THRB | P10828 | 2/20 | 0.56 |
| ▸ | ERCC5 | P28715 | 2/20 | 0.52 |
| ▸ | FEN1 | P39748 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1893700 | 0.90 | RXFP1 (0.78) | RXFP1MAPTTP53THRBGAA | |
| SCHEMBL1888933 | 0.87 | MAPT (0.60) | RXFP1MAPTTP53THRBERCC5 | |
| SCHEMBL1890325 | 0.81 | TP53 (0.55) | RXFP1MAPTTP53THRBGAA | |
| SCHEMBL1882663 | 0.81 | RXFP1 (0.64) | RXFP1MAPTTP53THRBGAA | |
| SCHEMBL1889858 | 0.80 | TP53 (0.70) | RXFP1MAPTTP53THRBGAA | |
| SCHEMBL1894492 | 0.80 | RXFP1 (0.57) | RXFP1MAPTTP53THRBGAA | |
| SCHEMBL1888480 | 0.75 | RXFP1 (0.54) | RXFP1MAPTTP53THRBGAA | |
| SCHEMBL1889926 | 0.75 | RXFP1 (0.53) | RXFP1MAPTTP53THRBERCC5 | |
| SCHEMBL1887674 | 0.75 | TP53 (0.64) | RXFP1MAPTTP53THRBERCC5 | |
| SCHEMBL1887201 | 0.73 | TP53 (0.56) | RXFP1MAPTTP53THRBERCC5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947691-B2 | Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof | ATHERSYS, INC. (US) | 2011-05-24 | — | — | US | claimed |
| US-20080287465-A1 | Cyclic N-Hydroxy Imides as Inhibitors of Flap Endonuclease and Uses Thereof | ATHERSYS, INC. (US) | 2008-11-20 | — | — | US | claimed |
| US-7947691-B2 | Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof | ATHERSYS, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-7947691-B2 | Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof | ATHERSYS, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-7947691-B2 | Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof | ATHERSYS, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-20080287465-A1 | Cyclic N-Hydroxy Imides as Inhibitors of Flap Endonuclease and Uses Thereof | ATHERSYS, INC. (US) | 2008-11-20 | — | — | US | disclosed |
| US-20080287465-A1 | Cyclic N-Hydroxy Imides as Inhibitors of Flap Endonuclease and Uses Thereof | ATHERSYS, INC. (US) | 2008-11-20 | — | — | US | disclosed |
| US-20080287465-A1 | Cyclic N-Hydroxy Imides as Inhibitors of Flap Endonuclease and Uses Thereof | ATHERSYS, INC. (US) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287465-A1 | Cyclic N-Hydroxy Imides as Inhibitors of Flap Endonuclease and Uses Thereof | FEN1, UNG, POLH | RXFP1 4698/4885MAPT 4773/4885TP53 476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.